Novartis has filed a patent for new amino pyrimidine derivatives that interact with Bruton’s tyrosine kinase (Btk). These derivatives have potential applications in the treatment of various diseases including autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, transplant rejection, and certain types of cancers. GlobalData’s report on Novartis gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Novartis AG - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Novartis, Cancer treatment biomarkers was a key innovation area identified from patents. Novartis's grant share as of September 2023 was 51%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230312483A1) describes a method for treating diseases that can be treated by modulating Bruton Tyrosine Kinase (BTK). The method involves administering a therapeutically acceptable amount of a compound of formula (I) to a patient in need of such treatment. The compound of formula (I) can be a compound itself or a pharmaceutically acceptable salt thereof.

The patent claims provide detailed information about the specific compounds that can be used in the method. The compounds of formula (I) have various substituents and functional groups, such as hydrogen, alkyl groups, halogen, hydroxy, cycloalkyl, azacyclic rings, alkenyl, alkynyl, and alkoxy. The compounds can also form bonds or rings with other atoms. The patent claims specify different variations of these compounds that can be used in the method.

The patent claims also mention that the diseases that can be treated by modulating BTK include autoimmune disorders, inflammatory diseases, and allergic diseases. Specific examples of diseases mentioned in the claims include asthma, chronic obstructive pulmonary disease (COPD), transplant rejection, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, diabetes, inflammatory bowel disease, various types of leukemia and lymphoma, and thromboembolic disorders.

Overall, the patent describes a method for treating diseases by modulating BTK using specific compounds of formula (I). The method has potential applications in the treatment of various autoimmune, inflammatory, and allergic diseases. The compounds mentioned in the patent claims provide a range of options for developing therapeutic interventions targeting BTK modulation.

To know more about GlobalData’s detailed insights on Novartis, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies